PMID- 23850495
OWN - NLM
STAT- MEDLINE
DCOM- 20131119
LR  - 20161125
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 44
IP  - 10
DP  - 2013 Oct
TI  - Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by 
      fluorescence in situ hybridization: the superiority of fluorescence in situ 
      hybridization over ERG immunohistochemistry.
PG  - 2227-33
LID - S0046-8177(13)00191-3 [pii]
LID - 10.1016/j.humpath.2013.05.005 [doi]
AB  - Small cell carcinoma of the prostate is both morphologically and 
      immunohistochemically similar to small cell carcinoma of other organs such as the 
      urinary bladder or lung. TMPRSS2-ERG gene fusion appears to be a highly specific 
      alteration in prostatic carcinoma that is frequently shared by small cell 
      carcinoma. In adenocarcinoma, immunohistochemistry for the ERG protein product 
      has been reported to correlate well with the presence of the gene fusion, 
      although in prostatic small cell carcinoma, this relationship is not completely 
      understood. We evaluated 54 cases of small cell carcinoma of the prostate and 
      compared TMPRSS2-ERG gene fusion status by fluorescence in situ hybridization 
      (FISH) to immunohistochemical staining with antibody to ERG. Of 54 cases of 
      prostatic small cell carcinoma, 26 (48%) were positive for TMPRSS2-ERG gene 
      fusion by FISH and 12 (22%) showed overexpression of ERG protein by 
      immunohistochemistry. Of the 26 cases positive by FISH, 11 were also positive for 
      ERG protein by immunohistochemistry. One tumor was positive by 
      immunohistochemistry but negative by FISH. Urinary bladder small cell carcinoma 
      (n = 25) showed negative results by both methods; however, 2 of 14 small cell 
      carcinomas of other organs (lung, head, and neck) showed positive 
      immunohistochemistry but negative FISH. Positive staining for ERG by 
      immunohistochemistry is present in a subset of prostatic small cell carcinomas 
      and correlates with the presence of TMPRSS2-ERG gene fusion. Therefore, it may be 
      useful in confirming prostatic origin when molecular testing is not accessible. 
      However, sensitivity and specificity of ERG immunohistochemistry in small cell 
      carcinoma are decreased compared to FISH.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Schelling, Lindsay A
AU  - Schelling LA
AD  - Department of Pathology and Laboratory Medicine, Indiana University School of 
      Medicine, Indianapolis, IN 46202, USA.
FAU - Williamson, Sean R
AU  - Williamson SR
FAU - Zhang, Shaobo
AU  - Zhang S
FAU - Yao, Jorge L
AU  - Yao JL
FAU - Wang, Mingsheng
AU  - Wang M
FAU - Huang, Jiaoti
AU  - Huang J
FAU - Montironi, Rodolfo
AU  - Montironi R
FAU - Lopez-Beltran, Antonio
AU  - Lopez-Beltran A
FAU - Emerson, Robert E
AU  - Emerson RE
FAU - Idrees, Muhammad T
AU  - Idrees MT
FAU - Osunkoya, Adeboye O
AU  - Osunkoya AO
FAU - Man, Yan-Gao
AU  - Man YG
FAU - Maclennan, Gregory T
AU  - Maclennan GT
FAU - Baldridge, Lee Ann
AU  - Baldridge LA
FAU - Comperat, Eva
AU  - Comperat E
FAU - Cheng, Liang
AU  - Cheng L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130712
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMPRSS2-ERG fusion protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Small Cell/*genetics/metabolism/pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology
MH  - Trans-Activators/metabolism
MH  - Transcriptional Regulator ERG
OTO - NOTNLM
OT  - Fluorescence in situ hybridization
OT  - Histogenesis
OT  - Molecular genetics
OT  - Neuroendocrine tumor
OT  - Prostate
OT  - Small cell carcinoma
OT  - TMPRSS2-ERG rearrangement
OT  - Tumor of unknown origin
EDAT- 2013/07/16 06:00
MHDA- 2013/11/20 06:00
CRDT- 2013/07/16 06:00
PHST- 2013/02/28 00:00 [received]
PHST- 2013/04/29 00:00 [revised]
PHST- 2013/05/01 00:00 [accepted]
PHST- 2013/07/16 06:00 [entrez]
PHST- 2013/07/16 06:00 [pubmed]
PHST- 2013/11/20 06:00 [medline]
AID - S0046-8177(13)00191-3 [pii]
AID - 10.1016/j.humpath.2013.05.005 [doi]
PST - ppublish
SO  - Hum Pathol. 2013 Oct;44(10):2227-33. doi: 10.1016/j.humpath.2013.05.005. Epub 
      2013 Jul 12.